- Home
- NRIX
as of 03-06-2026 3:41pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $29.46 | AVG Volume (30 days): | 706.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -3.05 | EPS Growth: | -5.90 |
| 52 Week Low/High: | $8.18 - $22.50 | Next Earning Date: | 05-01-2026 |
| Revenue: | $76,987,000 | Revenue Growth: | 99.31% |
| Revenue Growth (this year): | -24.11% | Revenue Growth (next year): | 26.32% |
| P/E Ratio: | -4.99 | Index: | N/A |
| Free Cash Flow: | -263467000.0 | FCF Growth: | N/A |
AI-Powered NRIX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nurix Therapeutics Inc. (NRIX)
Chief Legal Officer
Avg Cost/Share
$15.44
Shares
8,148
Total Value
$125,792.90
Owned After
34,601
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$16.66
Shares
14,261
Total Value
$237,618.21
Owned After
34,601
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$18.42
Shares
3,760
Total Value
$69,273.11
Owned After
34,601
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$18.21
Shares
3,760
Total Value
$67,314.32
Owned After
34,601
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Mar 2, 2026 | Sell | $15.44 | 8,148 | $125,792.90 | 34,601 | |
| Ring Christine | NRIX | Chief Legal Officer | Feb 9, 2026 | Sell | $16.66 | 14,261 | $237,618.21 | 34,601 | |
| Ring Christine | NRIX | Chief Legal Officer | Jan 20, 2026 | Sell | $18.42 | 3,760 | $69,273.11 | 34,601 | |
| Ring Christine | NRIX | Chief Legal Officer | Dec 18, 2025 | Sell | $18.21 | 3,760 | $67,314.32 | 34,601 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 28, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 28, 2026 · 100% conf.
1D
-1.33%
$17.63
Act: -1.57%
5D
-9.56%
$16.16
Act: -7.39%
20D
-9.41%
$16.19
Act: -9.85%
nrix-2026012800015495952025FYfalse00015495952026-01-282026-01-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2026
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3939827-0838048 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
1600 Sierra Point Parkway Brisbane, California 94005 (Address of Principal Executive Offices)(Zip Code)
(415) 660-5320 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareNRIXNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On January 28, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Exhibit Title or Description
99.1Press Release dated January 28, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NURIX THERAPEUTICS, INC.
Date: January 28, 2026 By:/s/ Arthur T. Sands Arthur T. Sands, M.D., Ph.D. President and Chief Executive Officer
3
2025 Q3 Q3 2025 Earnings
8-K Oct 9, 2025
Q3 2025 Earnings
8-KOct 9, 2025
nrix-2025100900015495952025FYfalse00015495952025-10-092025-10-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 9, 2025
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3939827-0838048 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California 94158 (Address of Principal Executive Offices)(Zip Code)
(415) 660-5320 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareNRIXNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On October 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2025. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Exhibit Title or Description
99.1Press Release dated October 9, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NURIX THERAPEUTICS, INC.
Date: October 9, 2025 By:/s/ Arthur T. Sands Arthur T. Sands, M.D., Ph.D. President and Chief Executive Officer
3
2025 Q2 Q2 2025 Earnings
8-K Jul 9, 2025
Q2 2025 Earnings
8-KJul 9, 2025
nrix-2025070900015495952025FYfalse00015495952025-07-092025-07-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3939827-0838048 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California 94158 (Address of Principal Executive Offices)(Zip Code)
(415) 660-5320 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareNRIXNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On July 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended May 31, 2025. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Exhibit Title or Description
99.1Press Release dated July 9, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NURIX THERAPEUTICS, INC.
Date: July 9, 2025 By:/s/ Arthur T. Sands Arthur T. Sands, M.D., Ph.D. President and Chief Executive Officer
3
Compare NRIX vs Leading Stocks
See how NRIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.